LONDON - BP (LON: BP) p.l.c. (NYSE: BP) announced today the appointment of David Hager as a non-executive director to its board, effective June 2, 2025.The addition of Hager, a seasoned professional ...

LONDON - BP p.l.c. (NYSE:BP) announced today the appointment of David Hager as a non-executive director to its board, effective June 2, 2025. The addition of Hager, a seasoned professional with ...

When: Donegal school board meeting, May 8. What happened: The board voted 8-1 to move forward with a 3.45% tax increase for the 2025-26 school year. Vice President Tim Markovits voted against ...

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the ... Kirsch was appointed to the Company’s Board of Directors. Mr. Kirsch has extensive ...

The Company expects to submit the New Drug Application for Xulane Lo in the second half of 2025. A low dose combination hormonal patch was found to be effective for pregnancy prevention based on ...

up from 3% in 2022. Even with electrical grid accommodations at a local utility level, these facilities are still at risk of unexpected power surge events. To optimize surge protection across a data ...

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less. Each advisor has been vetted by ...

Today, Johnson & Johnson announced promising new phase 3 data for icotrokinra (JNJ-2113), a first-in-class oral interleukin (IL)-23 receptor antagonist, showing that 75% of adolescents with ...

Today guest host Jay Ellis offered Jenna Bush Hager some valuable, if controversial, dating advice on the show this morning. The co-hosts were taking viewers’ questions and offering advice when ...

Jenna Bush Hager is a busy woman — and she's not afraid ... “So you’re in the phase. Okay. Just call me when you’re putting on Frozen for the 14th time.” “No, I’m not judging it ...

The phase 3 OVATION 3 trial will evaluate IMNN-001's efficacy and safety in advanced ovarian cancer patients, comparing it with standard chemotherapy. Phase 2 results demonstrated a 35% improvement in ...